Trinity Biotech plc ADR美股招股说明书(2026-06-23版)

Filed Pursuant to Rule 424(b)(3)Registration No. 333-293717 TRINITY BIOTECH PLC Secondary offering of up to33,752,429 American Depositary Sharesrepresenting675,048,580 Ordinary Shares This prospectus supplement updates and supplements the information contained in the prospectus dated June 16, 2026 (as may besupplemented or amended from time to time, the “Prospectus”), which forms a part of our Registration Statement on Form F-1, withinformation contained in our Report on Form 6-K, which was filed with the Securities and Exchange Commission on June 18, 2026(the “Current Reports”). Accordingly, we have attached the Current Report to this prospectus supplement. The prospectus, as it may be amended or supplemented from time to time, relates to the offer and resale by the Selling Shareholdersfrom time to time of up to 675,048,580 Ordinary Shares, represented by up to 33,752,429 ADSs. Our ADSs are listed for trading on the Nasdaq Global Select Market under the symbol “TRIB.” The last reported sale price of ourADSs on June 22, 2026 was $0.582. You should read the Prospectus, this prospectus supplement and any additional prospectus supplement or amendment carefully before Our business and an investment in our ADSs involve significant risks. These risks are described under the caption “Risk Factors”beginning on page 4 of the Prospectus and any other risk factors contained in any applicable prospectus supplement and in thedocuments incorporated by reference into the Prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securitiesor passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. The date of this prospectus supplement is June 23, 2026. SECURITIES AND EXCHANGE COMMISSIONWashington, D.C.20549 FORM6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2026 TRINITY BIOTECH PLC(Name of Registrant) IDA Business ParkBray, County. Wicklow, Ireland(Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F☒Form 40-F☐ This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070) and Form F-3 and (File Nos. 333-267160, 333-286020, 333-295842 and 333-280391). EXPLANATORY NOTE On June 23, 2026, the Company announced the launch of Trinovium, a new subsidiary focused on bringing healthcare‑grade fluidtechnology to the AI data centre liquid cooling market. A copy of the press release is filed herewith as Exhibit 99.1 EXHIBIT INDEX ExhibitDescription99.1Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-BillionDollar AI Data Center Liquid Cooling Market SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed onits behalf by the undersigned, thereunto duly authorized. TRINITY BIOTECH PLCTrinity Biotech plc(Registrant)By:/s/ Paul MurphyPaul MurphyInterim Chief Financial Officer Exhibit 99.1 Contact:Trinity Biotech plcPaul Murphy(353)-1-2769800 RedChip Companies Inc.Dave Gentry, CEO(1)-407-644-4256(1)-800-RED-CHIP (733-2447)TRIB@redchip.com Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-Billion DollarAI Data Center Liquid Cooling Market -New subsidiary will leverage existing US and EU manufacturing capacity, high-purity fluid expertise, and analytical technologies totarget liquid cooling performance and reliability in AI and high-performance computing environments -Data center liquid cooling market is projected to grow from $4 billion in 2026 to $27 billion by 20331 DUBLIN, Ireland and Wilsonville, Oregon (June 23, 2026) -Trinity Biotech plc (NASDAQ: TRIB), a commercial-stagebiotechnology company focused on human diagnostics and diabetes management solutions, today announced the launch of Trinovium,a dedicated subsidiary focused on advanced liquid cooling solutions and fluid intelligence systems for next-generation AI data centers.As escalating AI workloads increase compute density and heat generation, driving a rapid industry transition from air cooling toliquid-cooledinfrastructure,Trinovium will leverage Trinity's expertise in ultra-high-purity fluid manufacturing,analyticaltechnologies, and large-scale production capabilities to address the growing reliability challenges associated with next-generationliquid cooling systems. The data center liquid cooling market is projected to grow from $4 billion in 2026 to $27 billion by 2033, representing a 31.5% CAGR(2026, MarketsandMarkets)2, driven by increasing AI compute density and the growing adoption of liquid-cooled infrastructure.Independent industry rese